A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious disease, as well as new technologies to develop improved and innovative vaccines Validate marketing plans based on an analysis of the seven major categories of vaccines broken down by market share, revenues by region, and projected sales through 2015 Develop business strategies as new products, a general increase in public awareness, and more standardized immunization schedules converge to drive market growth Gain competitive insight into the burgeoning pipelines of vaccine manufacturers and suppliers, and how increasing investment in the research and development of new vaccines may affect your business. T: 866-285-7215, 1-781-489-7301 F: 781-489-7308 sales@bccresearch.com www.bccresearch.com
Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015. Introduction A vaccine is a pharmaceutical preparation of biological ingredients that provides immunity to a particular disease. are essential when administered in the form of a vaccination as they stimulate the body s immune system to produce antibodies without infecting the body with the actual disease. As such, the use of vaccines to immunize the body has become significantly important in reducing preventable infectious diseases. While some vaccines are powerful enough to provide the body with lifelong immunity, other vaccines require multiple doses or periodic injections or booster shots to provide lifelong immunity. are an essential innovation that scientists have taken many approaches to develop. Different vaccines are developed based on the nature of the virulent microorganism and how it functions within the body to produce the necessary immune response. Following are the different types of vaccines, which are utilized to stimulate an immune response within the body: Attenuated (Live) Inactivated (Killed) Toxoid Subunit Conjugate Recombinant Vector DNA. BCC Research report Technologies - PHM014D provides the information about the human and animal (veterinary) vaccines. It also provides detailed market analysis of human and animal (veterinary) vaccines along with the different factors affecting this market. The report has been useful to the Clinicians, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes. The information for the report has been collected through primary and secondary research methodologies by collecting the data through journals and through interviewing various analytical/chemical/pharmaceutical/biotechnical experts. SUMMARY FIGURE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008-2015 ($ MILLIONS) 60,000 50,000 $ Millions 40,000 30,000 20,000 10,000 0 2008 2009 2015 Human Animal Source: BCC Research
Scope of Study The global market for human vaccines in 2008 was $18.7 billion and, with a continuing increase in the global market, reached $21.2 billion in 2009. This market is expected to rise at a compound annual growth rate (CAGR) of 19.6% to reach $58.6 billion by the end of 2015. The scope of this report is broad and includes: Descriptions of various human and veterinary vaccines that treat infectious diseases, chronic infections, cancer, autoimmune diseases, allergies, high blood pressure and addictions Analysis of global market trends, with data from 2009, estimates for, and projections of compound annual growth rates (CAGRs) through 2015 The latest vaccine research findings in prophylactic and therapeutic areas Discussion of significant vaccine-related patents in the Unites States and Europe An overview of the regulatory environment. Table of Contents Chapter One: Introduction Study Objectives Reasons for Doing This Study Intended Audience Scope of The Study Methodology Information Sources About The Author Related Bcc Research Reports BCC Online Services Disclaimer Chapter Two: Executive Summary Executive Summary Summary Table Global Revenue of Human and Animal, Through Summary Figure Global Revenue of Human and Animal, 2008- Chapter Three: Overview What Is A Vaccine? History of Table 1 History of, 1996-2006 Types of Attenuated (Live) Applications of Attenuated (Live) Table 2 Applications of Attenuated (Live) Advantages and Disadvantages of Attenuated (Live) Table 3 Advantages and Disadvantages of Attenuated (Live) Inactivated (Killed) Applications of Inactivated (Killed) Table 4 Applications of Inactivated (Killed) Advantages and Disadvantages of Inactivated (Killed) Table 5 Advantages and Disadvantages of Inactived (Killed) Toxoid Applications of Toxoid Table 6 Applications of Toxoid Advantages and Disadvantages of Toxoid Table 7 Advantages and Disadvantages of Toxoid Subunit Applications of Subunit Table 8 Applications of Subunit Advantages and Disadvantages of Subunit Table 9 Advantages and Disadvantages of Subunit Conjugate Applications of Conjugate Table 10 Applications of Conjugate Advantages and Disadvantages of Conjugate Table 11 Advantages and Disadvantages of Conjugate Recombinant Vector Applications of Recombinant Vector Table 12 Applications of Recombinant Vector Advantages and Disadvantages of Recombinant Vector Table 13 Advantages and Disadvantages of Recombinant Vector DNA Applications of DNA Table 14 Applications of DNA Advantages and Disadvantages of DNA Table 15 Advantages and Disadvantages of DNA Infectious Diseases Preventable By Human Diseases Viral Diseases Table 16 Vaccine preventable Human Viral Diseases Bacterial Diseases Table 17 Vaccine preventable Human Bacterial Diseases Animal Diseases Table 18 Vaccine preventable Animal Diseases in Companion Animals Table 19 Vaccine preventable Animal Diseases in Livestock Animals Table 20 Livestock Animal Chapter Four: Prevalence Incidence and Immunization of Human Diseases Regional Data Table 21 Reported Incidence Data of Human Diseases, By Region, 2007-2009 Table 22 Immunization Coverage Data of Human Diseases, By Region, 2007-2009 (%) Global Data Table 23 Reported Cases of Human Diseases, 2007 and 2008 Table 24 Immunization Coverage of Human Diseases (%) Global Immunization Uptake Data Table 25 Uptake of New and Underused, 2008 Global Deaths Due To Vaccine preventable Diseases
The animal vaccines market grew from approximately $3.8 billion in 2008 to about $4.0 billion in 2009, an increase of about 5.9%. This market is expected to increase at a 5.7% compound annual growth rate (CAGR) between and 2015 to reach $5.6 billion in 2015. Table of Contents, Table 26 Global Child Deaths Due To Vaccine preventable Diseases, 2008 Chapter Five: Regulatory Aspects Table 27 Revisions To Existing, 2007- Table 28 New in The Global Market, 2007- Chapter Six: Industry Structure Who prequalified Vaccine Manufacturers/ suppliers Table 29 World Health Organization (Who) prequalified Manufacturers/Suppliers of Human, Manufacturers/Suppliers of Human Attenuated (Live) Table 30 Leading Manufacturers/Suppliers of Attenuated (Live) Inactivated (Killed) Table 31 Leading Manufacturers/Suppliers of Inactivated (Killed) Conjugate Table 32 Leading Manufacturers/suppliers of Conjugate Recombinant / Recombinant DNA (Rdna) Table 33 Leading Manufacturers/Suppliers of Recombinant/ Recombinant DNA (Rdna) Subunit Table 34 Leading Manufacturers/Suppliers of Subunit Toxoid Table 35 Leading Manufacturers/Suppliers of Toxoid Combination Table 36 Leading Manufacturers/Suppliers of Combination Market Shares of Industry Leaders of Human Attenuated (Live) Table 37 Global Market Shares of Manufacturers/ Suppliers of Attenuated (Live), 2009 (%) Figure 1 Global Market Shares of Manufacturers/ Suppliers of Attenuated (Live), 2009 (%) Inactivated (Killed) Table 38 Global Market Shares of Manufacturers/ Suppliers of Inactivated (Killed), 2009 (%) Figure 2 Global Market Shares of Manufacturers/ Suppliers of Inactivated (Killed), 2009 (%) Conjugate Table 39 Global Market Shares of Manufacturers/ Suppliers of Conjugate, 2009 (%) Figure 3 Global Market Shares of Manufacturers/ Suppliers of Conjugate, 2009 (%) Recombinant/Recombinant DNA (Rdna) Table 40 Global Market Shares of Manufacturers/ Suppliers of Recombinant/recombinant DNA (Rdna), 2009 (%) Figure 4 Global Market Shares of Manufacturers/ Suppliers of Recombinant/recombinant DNA (Rdna), 2009 (%) Subunit Table 41 Global Market Shares of Manufacturers/ Suppliers of Subunit, 2009 (%) Figure 5 Global Market Shares of Manufacturers/ Suppliers of Subunit, 2009 (%) Toxoid Table 42 Global Market Shares of Manufacturers/ Suppliers of Toxoid, 2009 (%) Figure 6 Global Market Shares of Manufacturers/ Suppliers of Toxoid, 2009 (%) Combination Table 43 Global Market Shares of Manufacturers/ Suppliers of Combination, 2009 (%) Figure 7 Global Market Shares of Manufacturers/ Suppliers of Combination, 2009 (%) Chapter Seven: New Developments New Developments Table 44 New Developments in The Research Pipeline of Human (As of August ) Chapter Eight: Market Analysis: Human Table 45 Global Market for Human By Region, Through Figure 8 Global Market for Human By Region, 2008- Attenuated (Live) Table 46 Global Market for Attenuated (Live), By Region, Through Figure 9 Global Market for Attenuated (Live), By Region, 2008- Inactivated (Killed) Table 47 Global Market for Inactivated (Killed), Through Figure 10 Global Market for Inactivated (Killed), 2008- Conjugate Table 48 Global Market for Conjugate, Through Figure 11 Global Market for Conjugate, 2008- Recombinant/Recombinant DNA (Rdna) Table 49 Global Market for Recombinant/ Recombinant DNA (Rdna), Through 2015 Figure 12 Global Market for Recombinant/ Recombinant DNA (Rdna), 2008-2015 Subunit Table 50 Global Market for Subunit, Through Figure 13 Global Market for Subunit, 2008- Toxoid Table 51 Global Market for Toxoid, Through Figure 14 Global Market for Toxoid, 2008- Combination Table 52 Global Market for Combination, By Region Through Figure 15 Global Market for Combination, By Region, 2008- Market Shares of Human, By Region Table 53 Global Human Market Shares By Region, 2009 (%) Figure 16 Global Human Market Shares By Region, 2009 (%) Market Shares of Human, By Type
Table of Contents, continued Table 54 Global Human Market Shares By Vaccine Type, 2009 (%) Figure 17 Global Human Market Shares By Vaccine Type, 2009 (%) Chapter Nine: Animal Health Market Industry Manufacturers of Animal Health Products Table 55 Global Animal Health Revenues By Market Leaders, 2008- Table 56 Global Animal Health Market Shares By Revenue, 2009 (%) Figure 18 Global Animal Health Market Shares By Revenue, 2009 (%) Animal Table 57 Global Market for Animal, Through Figure 19 Global Market for Animal, 2008- Chapter Ten: Market By Applications Humans Table 58 Diseases and Infections With Developed Human Based On Microorganism Table 59 Diseases and Infections With Developed Human Based On Treatment Meningococcal/Pneumococcal Diseases Table 60 Global Sales of Human in Meningococcal/ Pneumococcal Diseases Market, Through Figure 20 Global Sales of Human in Meningococcal/ Pneumococcal Diseases Market, 2008- Table 61 Top selling Groups of Meningococcal/ Penumococcal for 2009 By Market Share (%) Influenza (Seasonal and Pandemic) Diseases Table 62 Global Sales of Human in Influenza Diseases Market, Through Figure 21 Global Sales of Human in Influenza Diseases Market, 2008- Table 63 Top selling Groups of Influenza By Market Share, 2009 (%) Pediatric/Polio/Pertussis/Hib Diseases Table 64 Global Sales of Human in Pediatric/ Polio Pertussis/Hib Diseases Market, Through 2015 Figure 22 Global Sales of Human in Pediatric/ Polio/Pertussis/Hib Diseases Market, 2008- Table 65 Top selling Groups of Pediatric/Polio/ pertussis/hib By Market Share, 2009 (%) Adult/Adolescent Booster Related Diseases Table 66 Global Sales of Human in Adult/Adolescent Booster related Diseases Market, Through Figure 23 Global Sales of Human in Adult/ Adolescent Booster related Diseases Market, 2008- Table 67 Top selling Groups of Adult/Adolescent Booster related By Market Share, 2009 (%) Travel and Other Endemic Diseases Table 68 Global Sales of Human in Travel and Other Endemic Diseases Market, Through 2015 Figure 24 Global Sales of Human in Travel and Other Endemic Diseases Market, 2008-2015 Table 69 Top selling Groups of Travel and Other Endemic By Market Share, 2009 (%) HPV Disease Table 70 Global Sales of Human in Hpv Disease Market, Through Figure 25 Global Sales of Human in Hpv Disease Market, 2008- Table 71 Top selling Hpv in The Order of Their Sales, 2009 (%) Rotavirus Disease Table 72 Global Sales of Human in Rotavirus Disease Market, Through Figure 26 Global Sales of Human in Rotavirus Disease Market, 2008- Table 73 Top selling Rotavirus By Market Share, 2009 (%) Other Diseases Table 74 Global Sales of Human in Other Diseases Market, Through Figure 27 Global Sales of Human in Other Diseases Market, 2008- Table 75 Top selling Other for 2009 By Market Share (%) Market Share of Applications Table 76 Share of Various Categories of in The Human Market, 2009 (%) Figure 28 Share of Various Categories of in The Human Market, 2009 (%) Chapter Eleven: Patent Analysis Total Number of Patents Table 77 Number of Significant Patents, 2006 To Figure 29 Number of Significant Patents, 2006 To Figure 30 Percent of Significant Patents, 2006 To (%) Patents By Type and Year Table 78 Patents By Technology, 2006 To September Figure 31 Patents By Technology, 2006 To September Patents By Company Inactivated (Killed) Vaccine Technology Table 79 Number of U.S. Patents By Company Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Spetember Figure 32 Number of U.S. Patents By Company Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Attenuated (Live) Vaccine Technology Table 80 Number of U.S. Patents By Company Utilizing Attenuated (Live) Vaccine Technology, 2006 To Figure 33 Number of U.S. Patents By Company Utilizing Attenuated (Live) Vaccine Technology, 2006 To Conjugate Vaccine Technology Table 81 Number of U.S. Patents By Company Utilizing Conjugate Vaccine Technology, 2006 To Figure 34 Number of U.S. Patents By Company Utilizing Conjugate Vaccine Technology, 2006 To Toxoid Vaccine Technology Table 82 Number of U.S. Patents By Company Utilizing Toxoid Vaccine Technology, 2006 To
Table of Contents, continued Figure 35 Number of U.S. Patents By Company Utilizing Toxoid Vaccine Technology, 2006 To Recombinant/Rdna Vaccine Technology Table 83 Number of U.S. Patents By Company Utilizing Recombinant/rdna Vaccine Technology, 2006 To Figure 36 Number of U.S. Patents By Company Utilizing Recombinant/rdna Vaccine Technology, 2006 To Subunit Vaccine Technology Table 84 Number of U.S. Patents By Company Utilizing Subunit Vaccine Technology, 2006 To Figure 37 Number of U.S. Patents By Company Utilizing Subunit Vaccine Technology, 2006 To Other/Combined Vaccine Technology Table 85 Number of U.S. Patents By Company Utilizing Other/Combined Vaccine Technology, 2006 To Figure 38 Number of U.S. Patents By Company Utilizing Other/ Combined Vaccine Technology, 2006 To Patents By Country Inactivated (Killed) Vaccine Technology Table 86 Number of U.S. Patents By Country Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Figure 39 Number of U.S. Patents By Country Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Attenuated (Live) Vaccine Technology Table 87 Number of U.S. Patents By Country Utilizing Attenuated (Live) Vaccine Technology, 2006 To Figure 40 Number of U.S. Patents By Country Utilizing Attenuated (Live) Vaccine Technology, 2006 Conjugate Vaccine Technology Table 88 Number of U.S. Patents By Country Utilizing Conjugate Vaccine Technology, 2006 To September Figure 41 Number of U.S. Patents By Country Utilizing Conjugate Vaccine Technology, 2006 To September Table 89 Number of U.S. Patents By Country Utilizing Toxoid Vaccine Technology, 2006 To Figure 42 Number of U.S. Patents By Country Utilizing Toxoid Vaccine Technology, 2006 To Recombinant/ DNA/ Rdna Vaccine Technology Table 90 Number of U.S. Patents By Country Utilizing Recombinant/Dna/Rdna Vaccine Technology, 2006 To Figure 43 Number of U.S. Patents By Country Utilizing Recombinant/Dna/Rdna Vaccine Technology, 2006 To Subunit Vaccine Technology Table 91 Number of U.S. Patents By Country Utilizing Subunit Vaccine Technology, 2006 To September Figure 44 Number of U.S. Patents By Country Utilizing Subunit Vaccine Technology, 2006 To September Other/Combined Vaccine Technology Table 92 Number of U.S. Patents By Country Utilizing Other/Combined Vaccine Technology, 2006 To Figure 45 Number of U.S. Patents By Country Utilizing Other/Combined Vaccine Technology, 2006 To Table 93 Number of U.S. Patents By Country for All Vaccine Types, 2006 To (%) Figure 46 Patent Shares By Country for, 2006 To (%) Patents By Assignee Inactivated (Killed) Vaccine Technology Table 94 Patents By Assignee Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Figure 47 Patents By Assignee Utilizing Inactivated (Killed) Vaccine Technology, 2006 To Attenuated (Live) Vaccine Technology Table 95 Patents By Assignee Utilizing Attenuated (Live) Vaccine Technology, 2006 Through September Figure 48 Patents By Assignee Utilizing Attenuated (Live) Vaccine Technology, 2006 To Conjugate Vaccine Technology Table 96 Patents By Assignee Utilizing Conjugate Vaccine Technology, 2006 To Figure 49 Patents By Assignee Utilizing Conjugate Vaccine Technology, 2006 To Toxoid Vaccine Technology Table 97 Patents By Assignee Utilizing Toxoid Vaccine Technology, 2006 To Figure 50 Patents By Assignee Utilizing Toxoid Vaccine Technology, 2006 To Recombinant/Rdna Vaccine Technology Table 98 Patents By Assignee Utilizing Recombinant/ rdna Vaccine Technology, 2006 To Figure 51 Patents By Assignee Utilizing Recombinant/ rdna Vaccine Technology, 2006 To Subunit Vaccine Technology Table 99 Patents By Assignee Utilizing Subunit Vaccine Technology, 2006 To Figure 52 Patents By Assignee Utilizing Subunit Vaccine Technology, 2006 To Other/Combined Vaccine Technology Table 100 Patents By Assignee Utilizing Other/ Combined Vaccine Technology, 2006 To September Figure 53 Patents By Assignee Utilizing Other/ Combined Vaccine Technology, 2006 To September Chapter Twelve: Current Situation of The Global Market Facts About The Global Market Factors Affecting The Sales of Competition Cost Trends Immunization Funding Global Immunization Vision and Strategy (Givs) Table 101 Aims of Givs Table 102 Goals of Givs Table 103 Strategies of Givs Current Situation Table 104 Global Funding Gap By Region for Immunization Work, -2011 Vaccine Preventable Diseases Update Current Vaccine Prioritization Table 105 Vaccine Prioritization, 2009- Current and Future (Proposed) Vaccine Milestones Table 106 Vaccine Milestones 2009-2012 Influenza Virus Update for The Through 2011 Season Table 107 Influenza for The 2011 Season Chapter Thirteen: Company Profiles Advaxis Bayer Animal Health Bul Bio National Center of Infectious and Parasitic Diseases Ltd. (Bb ncipd Ltd.)
Table of Contents, continued Bharat Biotech Bio Farma Biological E. Limited Bio manguinhos Bioproperties Boehringer Ingelheim Vetmedica, Inc. Center for Genetic Engineering and Biotechnology Ceva Sante Animale Colorado Serum Company Crucell CSL Ltd. Eli Lilly & Co. Emergent Biosolutions Fatro Glaxosmithkline Green Cross Haffkine Bio pharmaceutical Corporation Ltd. Indovax Institut Pasteur De Dakar Intercell Japan Bcg Laboratory King Pharmaceuticals Inc. Lohmann International Medimmune Merck & Co., Inc. Nippon Biologicals, Inc. Novartis Ag Panacea Biotec Pfizer Inc. Romvac Sanofi aventis (Sanofi Pasteur) Serum Institute of India Ltd. Statens Serum Institut The Research Foundation for Microbial Diseases of Osaka University Ventri Biologicals Zydus Cadila Appendix I Abbreviations 199 pages 107 tables Related Reports DNA : Technologies ID: BIO067A Published: 09/09 ID: PHM014C Published: 01/08 Therapeutic : The Global Market ID: BIO052B Published: 03/10 About BCC Research BCC Research is a leading publisher of high-quality, technology market research reports and technical publications. BCC Research reports provide quantified measurements of the market and all major industry segments, as well as in-depth analysis of key market drivers and trends. BCC Subscriptions Access hundreds of published reports and automatically receive newly published research with a BCC Report Subscription. We can tailor a complete package of material that meets your needs and budget. BCC Custom Research Improve your strategic planning efforts with a BCC custom research study. We will work with you to determine what information is needed and deliver specific qualitative and quantitative analysis that supports your business objectives. Call 866-285-7215 or 1-781-489-7301 (intl), or e-mail sales@bccresearch.com for more information about any of BCC Research s products and services.